Actively Recruiting
Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-03-10
200
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment
CONDITIONS
Official Title
Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the diagnostic criteria for aplastic anemia (Camitta criteria)
- Receiving ATG/ALG immunosuppressive therapy for the first time
You will not qualify if you...
- Previously received hematopoietic stem cell transplantation
- Aplastic anemia patients receiving ATG/ALG as part of transplant conditioning regimen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Regenerative Medicine Center and Red Blood Cell Disorders Center
Tianjin, China
Actively Recruiting
Research Team
W
Weiwang Li, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here